This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sandoz, others file reply for judgment against US states' conspiracy claims in generic drug case

( April 7, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Sandoz, Glenmark, and other pharmaceutical companies filed a reply in support of a summary judgment against conspiracy claims filed by US states over generic drug pricing. “Not a single witness—not even those cooperating with the states—testified that there was any overarching agreement, and every witness that was asked (including those cooperating with the states) explicitly denied its existence. The states also failed to cite a single document supporting their overarching conspiracy theory. To the contrary, the undisputed evidence shows that defendants’ market shares differed widely and fluctuated in ways inconsistent with the existence of an agreement among all defendants,” they said.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections